**
Prostate cancer remains a significant health concern, with the UK witnessing approximately 55,000 new diagnoses each year. Recent guidance from medical experts suggests that only a select group of high-risk men should undergo regular testing for this prevalent condition. Understanding the symptoms and risk factors associated with prostate cancer is crucial for early detection and effective treatment.
What is Prostate Cancer?
The prostate is a walnut-sized gland located just below the bladder, encircling the urethra, the tube responsible for urine expulsion. Prostate cancer arises from the abnormal and uncontrolled growth of cells within this gland, often progressing slowly. Many individuals may experience no symptoms for years, and some might never encounter significant health issues related to the disease. However, in certain cases, prostate cancer can be aggressive and life-threatening. Early detection significantly enhances the chances of successful treatment.
In November 2025, the former Prime Minister, Lord Cameron, publicly disclosed his battle with prostate cancer, highlighting the disease’s impact on prominent figures.
Prevalence and Risk Factors
According to Prostate Cancer UK, one in eight men will receive a prostate cancer diagnosis in their lifetime, equating to around 55,000 new cases annually. Tragically, about 12,200 men succumb to the illness each year. The incidence is notably higher among older men, particularly those over 75, while cases in younger men are relatively rare.
Men with a family history of prostate cancer—such as fathers, brothers, or uncles—are at increased risk, as are black men, who face a significantly higher likelihood of developing the disease. Prostate Cancer UK offers a concise online risk assessment tool, encouraging individuals who believe they may be at higher risk to consult their GP.
Recognising Symptoms
Common symptoms of prostate cancer include:
– Increased frequency of urination, especially at night
– Difficulty initiating urination, weak urine flow, and prolonged urination
– Presence of blood in urine or semen
While these symptoms may arise from other medical conditions, it is essential for individuals to seek medical advice if they notice changes in urinary habits or other related issues.
Diagnostic Testing and Screening Recommendations
Currently, there is no singular diagnostic test for prostate cancer. Physicians typically utilise a combination of assessments, including a prostate-specific antigen (PSA) blood test, imaging scans, and biopsies, where a small tissue sample is examined for cancerous cells. A high PSA level does not automatically indicate cancer; it can also rise due to infections or other non-cancerous conditions.
Men over 50 wishing to undergo a PSA test can generally request one from their GP, who will provide information on the associated benefits and risks. It is advisable to avoid sexual activity and vigorous exercise for at least 48 hours prior to the test, as these factors may skew results. Additionally, healthcare professionals are exploring the potential of incorporating MRI scans alongside PSA testing to enhance diagnostic accuracy.
Current Screening Landscape
Despite its status as the most common cancer in the UK, prostate cancer lacks a universal screening programme. Advocacy from campaigners, including former cyclist Sir Chris Hoy, has highlighted the need for regular testing among high-risk groups. However, in November 2025, the UK National Screening Committee concluded that only a limited subset of high-risk men should be eligible for routine testing.
Their recommendations included:
– No universal screening for all men, citing potential harm outweighing benefits.
– No specific screening protocols for black men due to uncertainties surrounding efficacy.
– Regular screening every two years for men aged 45 to 61 who possess certain genetic mutations, known as BRCA variants.
The committee cautioned that screening could miss aggressive cancers while identifying indolent ones that might never require treatment, leading to unnecessary anxiety and procedures.
The response to the committee’s recommendations has been mixed. Cancer Research UK expressed support for the decision, particularly for men with BRCA gene mutations. In contrast, Prostate Cancer UK and Prostate Cancer Research voiced disappointment, especially regarding the lack of targeted screening for black men and those with a family history.
As the committee prepares to finalise its recommendations for ministers across the UK by March 2026, Health Secretary Wes Streeting has signalled his support for screening initiatives backed by robust evidence.
Treatment Options
Treatment for prostate cancer varies based on the cancer’s stage and aggressiveness. In cases where the cancer is in its early stages and not causing significant symptoms, a “watch and wait” approach may be recommended. For those requiring intervention, options include surgical removal of the prostate, radiotherapy, and hormone therapies aimed at slowing cancer progression. Other treatments, such as cryotherapy or high-intensity focused ultrasound, may also be considered to destroy cancer cells.
Why it Matters
Prostate cancer is a critical public health issue that affects a significant portion of the male population in the UK. With the potential for early detection and effective treatment, understanding risk factors, symptoms, and the current landscape of screening recommendations is vital. As advocacy continues for more inclusive testing strategies, the importance of awareness and education cannot be overstated in combating this prevalent disease.
